Source: NC BIOTECH, 6/14/22

A Morrisville biotech startup that is focused on revolutionizing current vaccination methods for the commercial poultry industry has landed an additional $35 million in funding.

TARGAN, formerly Applied LifeSciences & Systems, confirmed on Wednesday that it received the Series C equity financing co-led by Mountain Group Partners and NovaQuest Capital Management. Existing investors Merck Animal Health and Oval Park Capital also participated in the round. 

That brings its total raised to roughly $51.6 million since 2016.

“From its conception, TARGAN’s purpose has been to address the growing global demand for a healthier, more sustainable food supply through the development and application of novel technologies,” said TARGAN’s CEO and founder Ramin Karimpour. “We are most delighted that our great progress has led to NovaQuest joining our existing investors in this series.” 

For more of this story, click here.